BH3 mimetics selectively eliminate chemotherapy-induced senescent cells and improve response in TP53 wild-type breast cancer

CRISPResso2 provides accurate and rapid genome editing sequence analysis

(2019) Kendell Clement et al.   NATURE BIOTECHNOLOGY

Chemotherapy-induced senescent cancer cells engulf other cells to enhance their survival

(2019) Crystal A. Tonnessen-Murray et al.   JOURNAL OF CELL BIOLOGY

p53 Mediates Vast Gene Expression Changes That Contribute to Poor Chemotherapeutic Response in a Mouse Model of Breast Cancer

(2018) Crystal Tonnessen-Murray et al.   Translational Oncology

Intrinsic apoptotic pathway activation increases response to anti-estrogens in luminal breast cancers

(2018) Michelle M. Williams et al.   Cell Death & Disease

BH3-Mimetic Drugs: Blazing the Trail for New Cancer Medicines

(2018) Delphine Merino et al.   CANCER CELL

Exploiting the pro-apoptotic function of NOXA as a therapeutic modality in cancer

(2017) Jeroen E Guikema et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Differentially regulated gene expression in quiescence versus senescence and identification of ARID5A as a quiescence associated marker

(2017) Tarique Anwar et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1

(2017) T-C Teh et al.   LEUKEMIA

Senescence-associated reprogramming promotes cancer stemness

(2017) Maja Milanovic et al.   NATURE

Identification of a novel senolytic agent, navitoclax, targeting the Bcl-2 family of anti-apoptotic factors

(2016) Yi Zhu et al.   AGING CELL

TP53Variations in Human Cancers: New Lessons from the IARC TP53 Database and Genomics Data

(2016) Liacine Bouaoun et al.   HUMAN MUTATION

Key Survival Factor, Mcl-1, Correlates with Sensitivity to Combined Bcl-2/Bcl-xL Blockade

(2016) Michelle M. Williams et al.   MOLECULAR CANCER RESEARCH

The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models

(2016) András Kotschy et al.   NATURE

Directed elimination of senescent cells by inhibition of BCL-W and BCL-XL

(2016) Reut Yosef et al.   Nature Communications

Cellular Senescence Promotes Adverse Effects of Chemotherapy and Cancer Relapse

(2016) Marco Demaria et al.   Cancer Discovery

The Achilles’ heel of senescent cells: from transcriptome to senolytic drugs

(2015) Yi Zhu et al.   AGING CELL

TP53mutations are associated with higher rates of pathologic complete response to anthracycline/cyclophosphamide-based neoadjuvant chemotherapy in operable primary breast cancer

(2015) Yuxia Wang et al.   INTERNATIONAL JOURNAL OF CANCER

Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice

(2015) Jianhui Chang et al.   NATURE MEDICINE

Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancer

(2015) Anthony C. Faber et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Dynamin-related protein Drp1 is required for Bax translocation to mitochondria in response to irradiation-induced apoptosis

(2015) Ping Wang et al.   Oncotarget

An Inducible Lentiviral Guide RNA Platform Enables the Identification of Tumor-Essential Genes and Tumor-Promoting Mutations In Vivo

(2015) Brandon J. Aubrey et al.   Cell Reports

Secretome from senescent melanoma engages the STAT3 pathway to favor reprogramming of naive melanoma towards a tumor-initiating cell phenotype.

(2015) Mickaël Ohanna et al.   Oncotarget

CXCL5 Promotes Prostate Cancer Progression

(2015) Lesa A Begley et al.   NEOPLASIA

Enhancing Chemotherapy Efficacy in Pten -Deficient Prostate Tumors by Activating the Senescence-Associated Antitumor Immunity

(2014) Alberto Toso et al.   Cell Reports

Synthetic lethal metabolic targeting of cellular senescence in cancer therapy

(2013) Jan R. Dörr et al.   NATURE

14-3-3σ expression is associated with poor pathological complete response to neoadjuvant chemotherapy in human breast cancers

(2012) Yukiko Nakamura et al.   BREAST CANCER RESEARCH AND TREATMENT

Chemical Genomics Identifies Small-Molecule MCL1 Repressors and BCL-xL as a Predictor of MCL1 Dependency

(2012) Guo Wei et al.   CANCER CELL

p53-Mediated Senescence Impairs the Apoptotic Response to Chemotherapy and Clinical Outcome in Breast Cancer

(2012) James G. Jackson et al.   CANCER CELL

A CXCL1 Paracrine Network Links Cancer Chemoresistance and Metastasis

(2012) Swarnali Acharyya et al.   CELL

Comprehensive molecular portraits of human breast tumours

(2012) Daniel C. Koboldt et al.   NATURE

Value of TP53 Status for Predicting Response to Neoadjuvant Chemotherapy in Breast Cancer: A Meta-Analysis

(2012) Min-Bin Chen et al.   PLoS One

Senescence-associated secretory phenotype favors the emergence of cancer stem-like cells

(2012) J Cahu et al.   Cell Death & Disease

Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)

(2011) Laura J. Esserman et al.   BREAST CANCER RESEARCH AND TREATMENT

Drug-induced Senescence Generates Chemoresistant Stemlike Cells with Low Reactive Oxygen Species

(2011) Santhi Achuthan et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

SASP mediates chemoresistance and tumor-initiating-activity of mesothelioma cells

(2011) C Canino et al.   ONCOGENE

Sensitization of BCL-2-expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737

(2011) S. R. Oakes et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Nutlin-3, the small-molecule inhibitor of MDM2, promotes senescence and radiosensitises laryngeal carcinoma cells harbouring wild-type p53

(2010) A K Arya et al.   BRITISH JOURNAL OF CANCER

Haemotoxicity of busulphan, doxorubicin, cisplatin and cyclophosphamide in the female BALB/c mouse using a brief regimen of drug administration

(2010) Gemma Molyneux et al.   CELL BIOLOGY AND TOXICOLOGY

Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity

(2010) Wyndham H Wilson et al.   LANCET ONCOLOGY

Inflammatory networks during cellular senescence: causes and consequences

(2010) Adam Freund et al.   TRENDS IN MOLECULAR MEDICINE

Features of senescence and cell death induced by doxorubicin in A549 cells: organization and level of selected cytoskeletal proteins

(2009) Anna Litwiniec et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Cytokine expression and signaling in drug-induced cellular senescence

(2009) Z Novakova et al.   ONCOGENE

Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer

(2008) Cornelia Liedtke et al.   JOURNAL OF CLINICAL ONCOLOGY

Senescence-Associated Secretory Phenotypes Reveal Cell-Nonautonomous Functions of Oncogenic RAS and the p53 Tumor Suppressor

(2008) Jean-Philippe Coppé et al.   PLOS BIOLOGY